Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
JAMM AQUINO / JAQUINO @STARADVERTISER.COM State Epidemiologist Dr. Sarah Kemble said Thursday that the state Department of Health is not yet able to determine whether the specimen collected last week ...